Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lillian De Leon

Internal Medicine Chicago, IL Medical Doctor

NPI 1134142193 CMS profile 141777

2701 W 68Th St, 3Rd Floor Suite N, Chicago, IL 60629

Open in the dashboard

General payments

$8,518

418 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lillian De Leon of Chicago, IL is reported in the CMS Open Payments database as having received $8,518 across 418 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $934 48
2024 General $1,337 61
2023 General $1,324 57
2022 General $1,136 53
2021 General $1,261 66
2020 General $516 27
2019 General $2,011 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lillian De Leon
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Lillian De Leon were reported at $934. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Lillian De Leon Internal Medicine median Middle half National median
2019 $2,011 $159 $48–$570 $163
2020 $516 $119 $33–$402 $114
2021 $1,261 $135 $37–$521 $132
2022 $1,136 $141 $42–$496 $149
2023 $1,324 $149 $45–$519 $160
2024 $1,337 $154 $47–$537 $164
2025 $934 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,181 58 payments
  2. Lilly USA, LLC $1,080 51 payments
  3. AstraZeneca Pharmaceuticals LP $884 45 payments
  4. Amgen Inc. $716 42 payments
  5. Pfizer Inc. $665 26 payments
  6. Janssen Pharmaceuticals, Inc $597 26 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $563 23 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $446 16 payments
  9. Novo Nordisk Inc $418 22 payments
  10. Novartis Pharmaceuticals Corporation $367 16 payments
  11. Other $1,601 93 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,483 414 payments
  2. Education $35 4 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $819 42 payments
  2. ELIQUIS $634 24 payments
  3. MOUNJARO $625 30 payments
  4. XARELTO $591 25 payments
  5. FARXIGA $472 21 payments
  6. Kerendia $418 18 payments
  7. JARDIANCE $383 17 payments
  8. Prolia $377 21 payments
  9. EVENITY $331 18 payments
  10. Repatha $296 18 payments
  11. Other $5,426 305 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 104 drugs

Part D claims

6,237

Median for Internal Medicine: 777

Drug cost

$919,967

Median for Internal Medicine: $73,373

Branded share of claims

29.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 144 $127,595
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 111 $102,953
Eliquis Apixaban Brand 82 $92,777
Kerendia Finerenone Brand 76 $80,386
Jardiance Empagliflozin Brand 53 $77,726
Januvia Sitagliptin Phosphate Brand 46 $56,314
Ozempic Semaglutide Brand 51 $52,138
Linzess Linaclotide Brand 61 $47,652
Mounjaro Tirzepatide Brand 33 $42,236
Tradjenta Linagliptin Brand 42 $38,110

The 10 drugs with the highest cost, of 104 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$38,004

Medicare's payments for the services billed

Medicare patients

103

Average age 73

Services billed

725

85 women, 18 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 51%
Arthritis 42%
Chronic kidney disease 30%
Heart failure 17%
Ischemic heart disease 16%
Depression 14%
Osteoporosis 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $187
$187 144 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $129
$129 — —
JARDIANCE
  • Lilly USA, LLC $109
  • Boehringer Ingelheim Pharmaceuticals, Inc. $20
$129 53 —
MOUNJARO
  • Lilly USA, LLC $115
$115 33 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $107
$107 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

418 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record